This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): efalizumab, Xanelim
Description: Raptiva is a humanized monoclonal antibody that binds to an integrin (adhesion protein) present on many types of immune system cells.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
In April 1996, Xoma and Genentech partnered to develop Raptiva. On 1/12/2005, XOMA announced the restructuring of its agreement with Genentech. Key financial elements of the new agreement included:
* The cost and profit sharing arrangement in the United States was modified. XOMA will earn a mid-single digit royalty on worldwide sales of RAPTIVA with an additional royalty rate on sales in the United States in excess of a specified level. The original agreement provided XOMA with the option of electing a royalty-only participation in RAPTIVA results, with a higher worldwide royalty rate structure, but required immediate repayment of a development loan.
* In return, Genentech agreed to discharge XOMA's obligation to pay the $40 million balance on the development loan plus accrued interest and to allow repayment of XOMA's fourth quarter share of RAPTIVA operating losses by offsetting them against future royalties...See full deal structure in Biomedtracker
Partners: XOMA Corporation Merck KGaA PDL BioPharma, Inc.
Pink Sheet Another PML case associated with Raptiva
Additional information available to subscribers only: